Pharmacokinetic Drug Interaction Between Raloxifene and Cholecalciferol in Healthy Volunteers.
Ontology highlight
ABSTRACT: Osteoporosis is a common skeletal disorder, often leading to fragility fracture. Combination therapy with raloxifene, a selective estrogen receptor modulator, and cholecalciferol (vitamin D3 ) has been proposed to improve the overall efficacy and increase compliance of raloxifene therapy for postmenopausal osteoporosis. To our knowledge, there has been no report of any study on the pharmacokinetic interaction between raloxifene and cholecalciferol. This study aimed to evaluate the possible pharmacokinetic interactions between raloxifene and cholecalciferol in healthy adult male Korean volunteers. Twenty subjects completed this open-label, randomized, single-dose, 3-period, 6-sequence, crossover phase 1 study with a 14-day washout period. Serial blood samples were collected from
SUBMITTER: Lee HW
PROVIDER: S-EPMC9305550 | biostudies-literature | 2022 May
REPOSITORIES: biostudies-literature
ACCESS DATA